Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Non-Current Assets (2016 - 2025)

Integra Lifesciences Holdings' Non-Current Assets history spans 17 years, with the latest figure at $2.4 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 17.37% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $10.4 billion, down 9.79%, while the annual FY2025 figure was $2.4 billion, 17.37% down from the prior year.
  • Non-Current Assets for Q4 2025 was $2.4 billion at Integra Lifesciences Holdings, down from $2.5 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $3.0 billion in Q3 2024 and bottomed at -$1.1 billion in Q2 2022.
  • The 5-year median for Non-Current Assets is $2.7 billion (2021), against an average of $2.1 billion.
  • The largest annual shift saw Non-Current Assets crashed 147.96% in 2021 before it surged 350.79% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $2.6 billion in 2021, then increased by 3.79% to $2.7 billion in 2022, then dropped by 0.16% to $2.7 billion in 2023, then rose by 8.51% to $3.0 billion in 2024, then decreased by 17.37% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Non-Current Assets are $2.4 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.5 billion (Q2 2025).